Background/Aims: Several clinical trials have revealed various advantages for probiotics in inflammatory bowel disease (IBD). The aim of this study was to further investigate the effects of probiotic yogurt consumption on gut microbiota in patients with this disease. Methods: A total of 305 participants were divided into three groups; group A (IBD patients receiving probiotic yogurt; n=105), group B (IBD patients receiving placebo; n=105), and control group (healthy individuals receiving probiotic yogurt; n=95). Stool samples were collected both before and after 8 weeks of intervention; and population of Lactobacillus, Bifidobacterium and Bacteroides in the stool specimens was measured by Taqman real-time PCR method. Results: By the end of the intervention, no significant variations in the mean weight and body mass index were observed between three groups (p>0.05). However, the mean numbers of Lactobacillus, Bifidobacterium, and Bacteroides in group A were significantly increased compared to group B (p＜0.001, p＜0.001, and p＜0.01, respectively). There were also significant differences in the mean numbers of either of three bacteria between group A and the healthy control group; however, these differences between two groups were observed both at baseline and the end of the intervention. Conclusions: Consumption of probiotic yogurt by patients with IBD may help to improve intestinal function by increasing the number of probiotic bacteria in the intestine and colon. However, many more studies are required in order to prove the concept. (Korean J Gastroenterol 2015;65:215-221) 
INTRODUCTION
Inflammatory bowel disease (IBD) occurs in one of two forms, ulcerative colitis (UC) and Crohn's disease (CD), mainly in the second-to-forth decade of life, and with unknown etiology. 1, 2 The two forms of the disease closely resemble each other, so that it is difficult to distinguish between them, even pathologically; however, they are sufficiently different so that they are regarded as independent entities. 3 First, higher prevalence and incidence of IBD were reported in northern areas of Europe and America, 4, 5 and lower prevalence of the disease was reported among Asian people.
However, recent data show a rapid increase in prevalence of IBD, worldwide [6] [7] [8] ; particularly in Asia 9 and Iran, 10, 11 which is presumably the result of changes in the life style and nutritional habits of the habitants of these areas, high smoking, and development of new diagnostic tools for the disease. 12, 13 Human gut microbiota consists of more than one thousand species of bacteria, among which 99% belong to [24] [25] [26] [27] Several studies have reported that the use of probiotic products, particularly probiotic yogurt, has beneficial effects on intestinal function and gut microbiota in patients with UC and CD. [28] [29] [30] [31] For example, it is suggested that the probiotics, containing different strains of Lactobacillus and Bifidobacterium, are efficient in maintaining microbiota balance in the intestine. 20, 32 In addition, Ishikawa et al. 33 found that consumption of Bifidobacterium-fermented milk by patients with UC for one year decreased the stool concentration of Bacteroides; however, some controversial data have been reported. 34, 35 We conducted a clinical trial in order to investigate the effects of probiotic yogurt consumption on gut microbiota in patients with IBD using molecular approaches. The eligibility of participants was evaluated based on specific criteria.
SUBJECTS AND METHODS

Subjects
The patients were divided into two groups; group A or probiotic yogurt (n=105), and group B or placebo (n=105). A group of 95 healthy volunteers, who met inclusion criteria without IBD history, were also followed as the control group.
Various types of medications were used by the patients, including mesalazine, sulfasalazine, and budesonide. The participants had not used prebiotics, probiotics, antioxidants and omega 3 supplements and also antibiotics within the 3 months before the investigation. Patients with rheumatoid arthritis, diabetes, infectious and other gastrointestinal diseases, and lactating and pregnant women were excluded from the study. In addition, all participants were instructed to maintain the previous lifestyle, such as exercise, diet, and smoking during the period of the intervention.
Fiber and energy intake among subjects was assessed by a nutritionist through a three-day dietary recall, in which all changes in nutritional regime of the subjects were recorded at baseline and at the end of intervention. It was hypothesized that any changes in fiber and energy intake might be affected by intervention and or might affect the results.
Intervention
Both probiotic yogurt and placebo with 1.5% fat, in identi- In line with double-blind design, neither the patients nor the technicians knew the type of yogurt given to each patient. The healthy control group also consumed 250 g from probiotic yogurt for the same duration.
DNA extraction and real-time PCR assay
For evaluation of gut microbiota, before and at the end of the intervention, stool samples were collected from all participants and preserved at −20 o C. For homogenizing, 1 g of each stool sample was suspended in 9 mL of phosphate-buffered saline and centrifuged for 2 minutes, and then 200 L of each sample was taken for DNA extraction, using a QIAamp DNA stool mini kit according to the manufacturer's guidelines (Qiagen, Hilden, Germany). The obtained total DNA was pre-
Real-time PCR (Taqman method) was performed using the manufacturer's protocol (Qiagen). Briefly, 100 ng DNA and 600 nM of each primer were added to 12. 
Statistical analysis
Nutritionist IV software (The Hearst Corp., San Bruno, CA, USA) was used for analysis of the total nutrient intake. In all groups, for the data following normal and non-normal distribution, mean values before and after intervention were compared by paired t-test and Wilcoxon-signed ranks, respectively. The baseline mean value among groups was compared by one-way ANOVA test for normal data, and by
Kruskal-Wallis test for non-normal data. Linear regression test was used for monitoring the energy effect on nutrient intake. Data were expressed as mean±SD and p-value ＜ 0.05 was considered statistically significant.
Ethics
The and none of the participants had any problem with yogurt consumption.
RESULTS
As shown in Fig. 1 
Anthropometric features
The mean age and height of group A were 36.63±9.07 years old and 1.7±0.07 m, respectively; and no significant (p＞0.05) difference was found in comparison with group B (placebo) and the healthy group ( Table 2 ). The mean weight and BMI of the three groups are shown in Table 3 . No significant (p＞0.05) variations in the mean weight and BMI were observed between three groups, both at baseline and at the end of the intervention (Table 3) .
Nutrients intake
The results of mean energy and nutrient intake assessment via two recalls showed insignificant differences in the intake of protein, total fat, saturated fatty acid, monounsaturated fatty acid, polyunsaturated fatty acid, cholesterol, carbohydrate, calcium, and vitamin D between and also within the groups, both at baseline and at the end of the intervention (p＞0.05). Although the fiber intake was significantly different between group A and group B at the end of the intervention (p＜0.05), the energy intake showed no significant variation between two groups (p＞0.05).
Changes in Populations of Lactobacillus, Bifidobacterium, and Bacteroides
All the designed primers were completely specified for the target bacteria, not interfering with other microorganisms residing in the intestinal. As shown in probiotic yogurt by patients in group A. There was also a significant difference in the mean numbers of either Lactobacillus or Bifidobacterium or Bacteroides between group A and the healthy control group (p＜0.05, p＜0.05, and p＜0.001, respectively); however, these differences between two groups were observed both at baseline and the end of the intervention (Table 5 ). These findings demonstrate that the numbers of Lactobacillus, Bifidobacterium, and Bacteroides in patients with IBD might not change compared to healthy individuals, although regarding the well-known beneficial effects of such microorganisms, the observed increase in their numbers, following consumption of probiotic yogurt, might help to improve gut function in patients with IBD.
In addition, the increase in the numbers of either Lactobacillus or Bifidobacterium or Bacteroides at end of the intervention compared to the baseline were statistically sig- Bifidobacterium and Clostridium residing in the gastrointestinal tract convert the nutritional fibers into short chain fatty acids that provide 10% of the body energy. 15 In addition, in patients with CD the removal of carbohydrates from the nutrition schedule improved the disease outcome, suggesting a role for microbial fermentation in the pathogenesis of the disease. 20 In the current study, we observed a significant difference in fiber intake between the studied groups at the end of the intervention; however, the energy intake showed no significant difference. This result indicates that the consumption of probiotic yogurt might have affected the metabolism of fibers, which led to the body requiring further absorption of the fibers.
In conclusion, our findings indicate that consumption of probiotic yogurt by patients suffering from IBD may help to improve intestinal function by increasing the number of helpful bacteria such as Lactobacillus and Bifidobacterium in the intestine and colon. However, the probable side effects of these bacteria and the mechanisms by which they affect human health remains to be well-elucidated.
